Fujifilm to make drug unit a wholly-owned subsidiary

15 May 2018

Japanese conglomerate Fujifilm Holdings (TYO: 4901) will increase its stake in Toyama Chemical to 100% and merge it with an existing unit to create a new company focused on the swift development of new diagnostic and therapeutic drugs.

Toyama researches, develops, manufactures and sells small-molecule products, and has been 66%-owned by Fujifilm since 2008. Now the diversified tech firm is to buy the remaining 34% from Taisho Pharmaceutical Holdings.

The existing unit that the group plans to merge Toyama with is the radiopharmaceuticals specialist Fujifilm RI Pharma, further strengthening the relationship between diagnosis and treatment, and the new company is set to launch on October 1 of this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK